This is a Peanut Allergy Study.
summarize the methods section and summarize the resultssection:
Methods:
Infants between the age of 4 and 11 months who had severeeczema, egg allergy, or both were selected. There were two studycohorts (those who showed no sensitivity to peanuts, while theother group showed a wheal measuring 1 to 4 mm in diameter). Anyinfant that had a wheal greater than 4 mm was not selected for thestudy based on the risk of having a serious reaction. Each of thetwo cohorts was randomly assigned to an experimental group. Thecontrol group was given a diet that avoided peanut foods and theexposure group was fed 6 grams of peanut-containing foods spacedout into at least 3 different exposures per week until they reachedthe age of 60 months. Compliance was measured through a foodfrequency questionnaire and through testing of bedding at the ageof 60 months for peanut particulate matter to verify theirexposure. The actual numbers of male versus female participants wasnever clearly stated. However, 64.8% of the avoidance group weremales compared to 55.2% of the consumption group
Results:
Infants who did not have any response to the initial skin testwere given 5 grams of peanut in a single dose. The immune IgEresponse was measured to determine if an allergy was present. Forparticipants who had shown a small reaction to peanut initiallywere given a double blind placebo controlled trial where a total of9.4 grams of peanut were administered in increments to determine ifa current allergy was present (this was done to keep theparticipants safe from a severe reaction).
Among the 542 infants in the group with a negative result on theinitial skin-prick test, 530 (97.8%) could be evaluated for theprimary. At 60 months of age, 13.7% of the avoidance group and 1.9%of the consumption group were allergic to peanuts; this absolutedifference in risk of 11.8 percentage points (95% confidenceinterval [CI], 3.4 to 20.3; P<0.001) represents an 86.1%relative reduction in the prevalence of peanut allergy.
All 98 children in the group with positive results on theinitial skin-prick test were evaluated. At 60 months of age, 35.3%of the avoidance group and 10.6% of the consumption group wereallergic to peanuts; the absolute difference in risk of 24.7percentage points (95% CI, 4.9 to 43.3; P=0.004) represents a 70.0%relative reduction in the prevalence of peanut allergy.
This is a Peanut Allergy Study.
summarize the methods section and summarize the resultssection:
Methods:
Infants between the age of 4 and 11 months who had severeeczema, egg allergy, or both were selected. There were two studycohorts (those who showed no sensitivity to peanuts, while theother group showed a wheal measuring 1 to 4 mm in diameter). Anyinfant that had a wheal greater than 4 mm was not selected for thestudy based on the risk of having a serious reaction. Each of thetwo cohorts was randomly assigned to an experimental group. Thecontrol group was given a diet that avoided peanut foods and theexposure group was fed 6 grams of peanut-containing foods spacedout into at least 3 different exposures per week until they reachedthe age of 60 months. Compliance was measured through a foodfrequency questionnaire and through testing of bedding at the ageof 60 months for peanut particulate matter to verify theirexposure. The actual numbers of male versus female participants wasnever clearly stated. However, 64.8% of the avoidance group weremales compared to 55.2% of the consumption group
Results:
Infants who did not have any response to the initial skin testwere given 5 grams of peanut in a single dose. The immune IgEresponse was measured to determine if an allergy was present. Forparticipants who had shown a small reaction to peanut initiallywere given a double blind placebo controlled trial where a total of9.4 grams of peanut were administered in increments to determine ifa current allergy was present (this was done to keep theparticipants safe from a severe reaction).
Among the 542 infants in the group with a negative result on theinitial skin-prick test, 530 (97.8%) could be evaluated for theprimary. At 60 months of age, 13.7% of the avoidance group and 1.9%of the consumption group were allergic to peanuts; this absolutedifference in risk of 11.8 percentage points (95% confidenceinterval [CI], 3.4 to 20.3; P<0.001) represents an 86.1%relative reduction in the prevalence of peanut allergy.
All 98 children in the group with positive results on theinitial skin-prick test were evaluated. At 60 months of age, 35.3%of the avoidance group and 10.6% of the consumption group wereallergic to peanuts; the absolute difference in risk of 24.7percentage points (95% CI, 4.9 to 43.3; P=0.004) represents a 70.0%relative reduction in the prevalence of peanut allergy.
